Pharmacoeconomical aspects of chemotherapy in children at high risk of tuberculosis

Abstract

AIM: of the study is to analyze the results of pharmacoeconomical studies of preventive chemotherapy in children from high-risk groups of tuberculosis to optimize measures for the prevention of tuberculosis infection in children.

MATERIALS AND METHODS: Collection, systematization and analysis of data from the scientific literature and the results of their own research on the relevant problem.

RESULTS: On the problem of chemoprophylaxis of tuberculosis infection in children from high-risk groups, there is insufficient information on the pharmacoeconomical aspects of this problem. Most studies include a pharmacoeconomical assessment of the management of adult patients with tuberculosis infection. There are isolated scientific papers devoted to the pharmacoeconomical analysis of the preventive treatment of latent tuberculosis infection (LTI) in children. Different clinical and economic efficiency of the applied methods of immunodiagnostics and regimens of chemoprophylaxis of tuberculosis in children is shown. To improve the epidemic situation of tuberculosis among children, it is important to improve preventive chemotherapy regimens. Their effectiveness is largely determined by the sensitivity of Mycobacterium tuberculosis (MBT) to anti-tuberculosis drugs (PTP) and the rational choice of a chemotherapy regimen. The current chemoprophylaxis regimens for children with LTI do not take into account the sensitivity of MBT to PTP at a possible source of infection.

CONCLUSION: The analysis shows the high relevance of pharmacoeconomical studies and the practical significance of the results of such studies for optimizing preventive chemotherapy in children from high-risk groups for tuberculosis. Scientific research on the assessment of the clinical and economic effectiveness of various regimens of chemoprophylaxis of tuberculosis in children allows us to identify the most effective and least expensive ways to prevent tuberculosis through the rational use of medicines and methods of immunodiagnostics.

Keywords

pharmacoeconomics / tuberculosis infection in children / preventive chemotherapy / anti-tuberculosis drugs

References

[1] Аksenova VA, Klevno NI, Kazakov AV, et al. Preventive chemotherapy in children exposed to multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases. 2019;97(6):36–43. (In Russ.) DOI: 10.21292/2075-1230-2019-97-6-36-43

[2] Аксенова В.А., Клевно Н.И., Казаков А.В., и др. Превентивная химиотерапия у детей из очагов туберкулеза с множественной лекарственной устойчивостью возбудителя // Туберкулез и болезни легких. 2019. Т. 97, № 6. С. 36–43. DOI: 10.21292/2075-1230-2019-97-6-36-43

[3] Frolova JV, Myakisheva TV. Efficiency of screening for tuberculosis infection in children population. Vestnik of the Smolensk state medical academy. 2017;16(1):148–152. (In Russ.)

[4] Фролова Ю.В., Мякишева Т.В. Скрининговые обследования детского населения на туберкулезную инфекцию и их эффективность // Вестник Смоленской государственной медицинской академии. 2017. Т. 16, № 1. С. 148–152.

[5] Kolomiets VM, Dremova NB, Abramov AV, et al. Pharmacological and economic analysis of the efficiency of tuberculosis treatment in the condition of hospital. Kursk Scientific and Practical Bulletin “Man and His Health”. 2011;(1):45–50. (In Russ.)

[6] Коломиец В.М., Дрёмова Н.Б., Абрамов А.В., и др. Фармакоэкономический анализ эффективности основного курса лечения туберкулеза в условиях стационара // Курский научно-практический вестник «Человек и его здоровье». 2011. № 1. С. 45–50.

[7] Podgayeva VA, Golubev DN, Chernyaev IA, Shulev PL. Pharmacoeconomical cost assessment of hospital treatment in patients with multidrug resistant tuberculosis. Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2011;4(1):71–72. (In Russ.)

[8] Подгаева В.А., Голубев Д.Н., Черняев И.А., и др. Фармакоэкономическая оценка стоимости стационарного лечения больных туберкулезом с множественной лекарственной устойчивостью возбудителя // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2011. Т. 4, № 1. С. 71–72.

[9] Svistunov AA, Yagudina RI, Abdrashitova GT, et al. Pharmacoeconomic analysis in various nosologies. Sechenov Medical Journal. 2016;24(2):42–50. (In Russ.)

[10] Свистунов А.А., Ягудина Р.И., Абдрашитова Г.Т., и др. Особенности проведения фармакоэкономического анализа при различных нозологиях // Сеченовский вестник. 2016. Т. 24, № 2. С. 42–50.

[11] Diel R, Wrighton-Smith P, Zellweger J-P. Cost-effectiveness of interferon-c release assay testing for the treatment of latent tuberculosis. Eur Respir J. 2007;30(2):321–332. DOI: 10.1183/09031936.00145906

[12] Diel R., Wrighton-Smith P., Zellweger J.-P. Cost-effectiveness of interferon-c release assay testing for the treatment of latent tuberculosis // Eur Respir J. 2007. Vol. 30. No. 2. P. 321–332. DOI: 10.1183/09031936.00145906

[13] Koufopoulou M, Sutton A, Breheny K, et al. Methods Used in Economic Evaluations of Tuberculin Skin Tests and Interferon Gamma Release Assays for the Screening of Latent Tuberculosis Infection: A Systematic Review. Value in health. 2016;19(2):267–276. DOI: 10.1016/j.jval.2015.11.006

[14] Koufopoulou M., Sutton A., Breheny K., et al. Methods Used in Economic Evaluations of Tuberculin Skin Tests and Interferon Gamma Release Assays for the Screening of Latent Tuberculosis Infection: A Systematic Review // Value in health. 2016. Vol. 19. No. 2. P. 267–276. DOI: 10.1016/j.jval.2015.11.006

[15] Solodun IYu, Holownia M, Bashlakova EE, et al. Clinical and economic analysis of methods of diagnosis of tuberculosis infection in children and adolescents by using recombinant tuberculous allergen. Health care Standardization Problems. 2017;(3–4):49–56. (In Russ.)

[16] Солодун И.Ю., Холовня М.Э., Башлакова Е.Е., и др. Клинико-экономический анализ применения метода диагностики туберкулезной инфекции у детей и подростков с использованием аллергена туберкулезного рекомбинантного // Проблемы стандартизации в здравоохранении. 2017. № 3–4. С. 49–56.

[17] Yagudina RI, Zinchuk IYu. Pharmacoeconomic study of skin tests in the diagnostics of tuberculosis infection. Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2013;6(1):11–15. (In Russ.)

[18] Ягудина Р.И., Зинчук И.Ю. Фармакоэкономическое исследование лекарственных средств для диагностики туберкулезной инфекции // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2013. Т. 6, № 1. С. 11–15.

[19] Ignatyeva VI, Avxentyeva MV, Omelyanovsky VV, Khachatryan GR. Modeling clinical and economic outcomes of testing for LTBI with T-SPOT.TB in immunocompromised children. Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014;7(3):12–19. (In Russ.)

[20] Игнатьева В.И., Авксентьева М.В., Омельяновский В.В., Хачатрян Г.Р. Клинико-экономическое моделирование результатов использования T-SPOT.TB у иммуноскомпрометированных детей // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2014. Т. 7, № 3. С. 12–19.

[21] Baronova OD, Aksenova VA, Klevno NI, et al. Safety and medical cost effectiveness of preventive treatment of children with latent tuberculosis infection. Tuberculosis and Lung Diseases. 2020;98(9): 25–31. (In Russ.) DOI: 10.21292/2075-1230-2020-98-9-25-31

[22] Баронова О.Д., Аксенова В.А., Клевно Н.И., и др. Безопасность и медико-экономическая эффективность превентивного лечения детей с латентной туберкулезной инфекцией // Туберкулез и болезни легких. 2020. Т. 98, № 9. С. 25–31. DOI: 10.21292/2075-1230-2020-98-9-25-31

[23] Johnson KT, Churchyard GJ, Sohn H, et al. Cost-effectiveness of Preventive Therapy for Tuberculosis with Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. Clin Infect Dis. 2018;67(7):1072–1078. DOI: 10.1093/cid/ciy230

[24] Johnson K.T., Churchyard G.J., Sohn H., et al. Cost-effectiveness of Preventive Therapy for Tuberculosis with Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings // Clin Infect Dis. 2018. Vol. 67. No. 7. P. 1072–1078. DOI: 10.1093/cid/ciy230

[25] Holland DP, Sanders GD, Hamilton CD, et al. Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection. PLoS ONE. 2011;6(7): e22276. DOI:10.1371/journal.pone.0022276

[26] Holland D.P., Sanders G.D., Hamilton C.D., et al. Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection // PLoS ONE. 2011. Vol. 6. No. 7. P. e22276. DOI:10.1371/journal.pone.0022276

[27] Marks SM, Mase SR, Morris SB. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2017;64(12):1670–1677. DOI: 10.1093/cid/cix208

[28] Marks S.M., Mase S.R., Morris S.B. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis // Clin Infect Dis. 2017. Vol. 64. No. 12. P. 1670–1677. DOI: 10.1093/cid/cix208.

[29] Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2009;179:1055–1060. DOI: 10.1164/rccm.200901-0153OC

[30] Holland D.P., Sanders G.D., Hamilton C.D., Stout J.E. Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection // Am J Respir Crit Care Med. 2009. Vol. 179. P. 1055–1060. DOI: 10.1164/rccm.200901-0153OC

[31] Klinicheskie rekomendatsii Rossiiskogo obshchestva ftiziatrov “Latentnaya tuberkuleznaya infektsiya u deteI” [cited 14.03.2021]. Available from: http://roftb.ru/netcat_files/doks2017/kl_1.pdf.

[32] Клинические рекомендации Российского общества фтизиатров «Латентная туберкулезная инфекция у детей». Дата обращения 14.03.2021. Доступ по ссылке: http://roftb.ru/netcat_files/doks2017/kl_1.pdf

[33] Denti P, Garcia-Prats AJ, Draper HR, et al. Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2018;62(2): e01521–17. DOI: 10.1128/AAC.01521-17

[34] Denti P., Garcia-Prats A.J., Draper H.R., et al. Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis // Antimicrob Agents Chemother. 2018. Vol. 62. No. 2. P. e01521–17. DOI: 10.1128/AAC.01521-17

[35] Novikov VE, Klimkina EI. Farmakologiya gepatoprotektorov. Reviews on clinical pharmacology and drug therapy. 2005;4(1):2–20. (In Russ.)

[36] Новиков В.Е., Климкина Е.И. Фармакология гепатопротекторов // Обзоры по клинической фармакологии и лекарственной терапии. 2005. Т .4, № 1. С. 2–20.

[37] Novikov VE, Klimkina EI. Effects of hypoxen on morphological and functional state of the liver under of exogenous intoxication conditions. Experimental and clinical pharmacology. 2009;72(5):43–45. (In Russ.)

[38] Новиков В.Е., Климкина Е.И. Влияние гипоксена на морфофункциональное состояние печени при экзогенной интоксикации // Экспериментальная и клиническая фармакология. 2009. Т. 72, № 5. С. 43–45.

[39] Levchenkova OS, Novikov VE. Antihypoxants: possible mechanisms of action and their clinical uses. Vestnik of the Smolensk state medical academy. 2011;10(4):43–57. (In Russ.)

[40] Левченкова О.С., Новиков В.Е. Антигипоксанты: возможные механизмы действия и клиническое применение // Вестник Смоленской государственной медицинской академии. 2011. Т. 10, № 4. С. 43–57.

[41] Pozhilova EV, Novikov VE, Levchenkova OS. Reactive oxygen species in cell physiology and pathology. Vestnik of the Smolensk state medical academy. 2015;14(2):13–22. (In Russ.)

[42] Пожилова Е.В., Новиков В.Е., Левченкова О.С. Активные формы кислорода в физиологии и патологии клетки // Вестник Смоленской государственной медицинской академии. 2015. Т. 14, № 2. С. 13–22.

[43] Pogilova EV, Novikov VE, Levchenkova OS. The mitochondrial ATP-dependent potassium channel and its pharmacological modulators. Reviews on clinical pharmacology and drug therapy. 2016;14(1):29–36. (In Russ.) DOI: 10.17816/RCF14129-36

[44] Пожилова Е.В., Новиков В.Е., Левченкова О.С. Митохондриальный АТФ-зависимый калиевый канал и его фармакологические модуляторы // Обзоры по клинической фармакологии и лекарственной терапии. 2016. Т. 14, № 1. С. 29–36. DOI: 10.17816/RCF14129-36.

[45] Usacheva NE, Novikov VE, Myakisheva YV, et al. Structural changes in the russian pharmaceutical market of anti-tb drugs. Reviews on clinical pharmacology and drug therapy. 2020;18(3): 245–254. (In Russ.) DOI:10.17816/RCF183245-254

[46] Усачева Н.Э., Новиков В.Е., Мякишева Т.В., и др. Структурные изменения российского фармацевтического рынка противотуберкулезных препаратов // Обзоры по клинической фармакологии и лекарственной терапии. 2020. Т. 18, № 3. С. 245–254. DOI: 10.17816/RCF183245-254

[47] Tsiligiannis A, Sfouni M, Nalda-Molina R, et al. Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis. Eur J Pharm Sci. 2019;138:105016. DOI: 10.1016/j.ejps.2019.105016.

[48] Tsiligiannis A., Sfouni M., Nalda-Molina R., et al. Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis // Eur J Pharm Sci. 2019. Vol. 138. ID105016. DOI: 10.1016/j.ejps.2019.105016.

RIGHTS & PERMISSIONS

Novikov V.E., Usacheva N.E., Ponamareva N.S., Myakisheva T.V.